1 H NMR (400 MHz, DMSO) 8.72 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 6.5 Hz, 9H), 7.14 (dd, J = 7.3, 2.5 Hz, 6H), 7.08 (s, 1H), 6.94 (t, J = 5.7 Hz, 1H), 6.75 (t, J = 5.8 Hz, 1H), 4.71 (s, 1H), 4.13 (td, J = 8.2, 5.2 Hz, 1H), 3.52 (d, J = 5.7 Hz, 2H), 3.07 (d, J = 14.8 Hz, 1H), 2.85 (dd, J = 16.6, 8.5 Hz, 3H), 1.35 (s, 24H)
Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.)
* Availability can vary by dose strength and pharmacy
Sources: Drug Shortages | FDA FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA Facts About the Current Good Manufacturing Practice (CGMP) | FDA FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products | FDA FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown